Contact your Representative about H.R. 3

The U.S. House of Representatives recently passed H.R. 3, a drug pricing package which includes significant changes to Medicare and the drug reimbursement system across the United States. The bill could reduce biopharmaceutical industry revenues by $1 trillion over the next decade and put nearly 1 million U.S. jobs at risk.  H.R. 3 could also lead to 100 fewer drugs entering the U.S. market, denying patients access to lifesaving cures.  We urge you to take action and thank your representative if he/she voted against H.R. 3 or express disappointment if he/she voted “yes” on this proposal.